BLU2864

Overview

BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor ( IC 50 =0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research .

Application

Products | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Prostate Cancer | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PKA

Product Information

• Catalog No.: HY-150076
• CAS No.: 2810747-89-6
• Molecular Formula: C24H19F3N4O2
• Molecular Weight: 452.43
• Purity: 99.50%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (5.53 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source